Latest News and Press Releases
Want to stay updated on the latest news?
-
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
-
Liminatus announces plan to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody.